drugset / Trial / NCT00143104

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143104 ↗

Phase 2 Completed 20 enrolled Pfizer Sanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.

Timeline

Start
2004-12
Primary completion
—
Completion
2006-10

Outcome

Met primary endpoint

release “patients using the Lilly/Alkermes inhaled insulin system achieved blood sugar levels similar to patients treated with injected insulin.” alkermes.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic — Inhaled